Scaleup programmes
Back to programmesProgramme
Livingbridge
Finance and Risk Capital
Impact for scaleups
14
UK companies backed
13%
follow on investments
57%
Investments outside of London
2
Growth-stage investments
Key sectors
Livingbridge is a private equity firm with more than 25 years’ experience, having made over 170 investments across four sectors – technology, services, healthcare & education, and consumer. It typically invests between £15 million and £300 million, taking both majority and minority stakes, and has a flexible approach which includes providing growth capital as well as funding management buy-outs, secondary buy-outs and replacement capital deals. It targets high-growth, entrepreneurial businesses with enterprise values of up to £300 million and currently manages approximately £3.5 billion in assets.
In the period between 2018 to June 2025, the firm invested in 14 UK companies in 16 fundraising rounds. The average turnover of those companies was £33m and their average number of employees was 587.
Livingbridge has a long history of funding scaleups such as Absolute Collagen a firm specialising in beauty products and Exclaimer a firm that produces specialised application software.
The firm has offices in London, Birmingham and Manchester and an Australian office in Melbourne to make primary investments in the UK, Australia and New Zealand. It has an office in Boston and a US industry advisory board to support expansion and M&A in the US.
Livingbridge has focused on both significant portfolio exits and a strong emphasis on its Responsible Investment programme in the UK during 2025. The firm achieved a major exit with the sale of the UK-based commercial insurance distribution platform Jensten Group to Bain Capital, highlighting its success in scaling up financial services businesses. Furthermore, Livingbridge published its 2024-25 Responsible Investment report, where it stressed a shift from setting commitments to driving delivery on its ESG goals, including implementing a structured engagement programme to support its portfolio companies in achieving science-based targets.
